Caution Needed When Updating Europe's Orphan Drugs Procedures, Industry Says
This article was originally published in SRA
The European Federation of Pharmaceutical Industries and Associations is urging caution in any updating or revising of Europe’s orphan drug procedures. The current process “works well, corrects a market failure and has allowed industry to develop more than 100 orphan drugs for more than 81 rare disorders,” the association told Scrip Regulatory Affairs.
Register for our free email digests: